United Kingdom

Arbutus Biopharma Corp (ABUS.OQ)

ABUS.OQ on NASDAQ Stock Exchange Global Select Market

21 Feb 2018
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Arbutus’ LNP licensee Alnylam initiates rolling submission of NDA for Patisiran
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Arbutus Biopharma Corp ::Arbutus’ LNP licensee Alnylam initiates rolling submission of New Drug Application (NDA) to U.S. Food and drug Administration (fda) for Patisiran.Says Alnylam expects to submit final clinical data for Patisiran by year end ​.  Full Article

Arbutus Biopharma reports Q3 loss per share $0.21
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Arbutus Biopharma Corp :Arbutus Biopharma Corp announces corporate update and third quarter 2017 financial results.Q3 non-GAAP loss per share $0.17.Q3 loss per share $0.21.Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S.  Full Article

Gritstone Oncology and Arbutus Biopharma announce LNP technology licensing agreement
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Arbutus Biopharma Corp : :Gritstone Oncology and Arbutus Biopharma announce LNP technology licensing agreement to develop novel RNA-based personalized neoantigen immunotherapies for cancer patients.Arbutus Biopharma Corp - is deploying proprietary lipid nanoparticle technology to deliver gritstone's rna-based neoantigen immunotherapy products​.Arbutus Biopharma - ‍under terms of license agreement, gritstone obtains worldwide access to arbutus' portfolio of proprietary and LNP products​.Arbutus Biopharma - ‍Gritstone will pay co upfront payment, payments for achievement of development, regulatory, and commercial milestones.  Full Article

Arbutus provides additional data from the ARB-1467 phase II clinical trial in HBV patients
Monday, 12 Dec 2016 

Arbutus Biopharma Corp : Arbutus Biopharma - one patient in cohort 2 discontinued treatment due to transient elevation of transaminases with normal bilirubin observed . Arbutus Biopharma Corp - company plans to add another cohort to ARB-1467 study to explore bi-weekly administration of 0.4 mg/kg dose . Arbutus Biopharma Corp - complete cohort 1 and 2 ARB-1467 multi-dose data demonstrate dose-responsive hbsag reductions . Arbutus Biopharma Corp - treatment with arb-1467 has been generally well tolerated in this study to date .Arbutus provides additional data from the ARB-1467 phase ii clinical trial in HBV patients.  Full Article

Arbutus Biopharma Q2 loss per share $2.47
Thursday, 4 Aug 2016 

Arbutus Biopharma Corp : Q2 loss per share $2.47 . Q2 revenue view $1.7 million -- Thomson Reuters I/B/E/S . Arbutus provides corporate update and announces second quarter 2016 financial results . Q2 revenue $300,000 versus $3.4 million . Q2 earnings per share view $-0.39 -- Thomson Reuters I/B/E/S . Says on track to deliver clinical data from lead hbv program arb-1467 in second half of this year . Says "thorough preclinical research efforts have led us to discontinue tlr9 program" .Says discontinuance of tlr9 program triggering a non-cash in-process research and development impairment charge of $156 million in q2.  Full Article

BRIEF-Arbutus Enters Exclusivity Agreement With Roivant Sciences

* ARBUTUS ENTERS EXCLUSIVITY AGREEMENT WITH ROIVANT SCIENCES Source text for Eikon: Further company coverage: ( Bangalore.newsroom@thomsonreuters.com )